(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.29%) $79.18
(0.00%) $2.04
(0.11%) $2 312.10
(0.25%) $26.90
(0.08%) $963.40
(-0.03%) $0.932
(-0.05%) $10.99
(-0.06%) $0.797
(-0.01%) $91.12
@ $110.27
Išleistas: 2 geg. 2024 @ 21:58
Grąža: -0.89%
Ankstesnis signalas: geg. 2 - 17:13
Ankstesnis signalas:
Grąža: 0.31 %
Live Chart Being Loaded With Signals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 1.05M |
Vidutinė apimtis | 615 163 |
Rinkos kapitalizacija | 6.81B |
EPS | $0 ( 2024-02-28 ) |
Kita pelno data | ( $4.16 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 17.92 |
ATR14 | $10.35 (9.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Gala Renee D | Sell | 1 736 | Ordinary Shares |
2024-03-06 | Carr Patricia | Sell | 1 236 | Ordinary Shares |
2024-03-06 | Carr Patricia | Sell | 700 | Ordinary Shares |
2024-03-07 | Carr Patricia | Sell | 1 768 | Ordinary Shares |
2024-03-05 | Gala Renee D | Sell | 3 622 | Ordinary Shares |
INSIDER POWER |
---|
43.50 |
Last 96 transactions |
Buy: 357 937 | Sell: 150 837 |
Tūris Koreliacija
Jazz Pharmaceuticals PLC Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
SLVO | 0.91 |
DTSS | 0.903 |
DCRC | 0.887 |
FNWD | 0.875 |
AZTA | 0.874 |
NAKD | 0.873 |
MRNA | 0.866 |
BMRN | 0.864 |
PIXY | 0.861 |
INVA | 0.86 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
NRDS | -0.922 |
MORF | -0.92 |
HYPR | -0.909 |
MYNA | -0.908 |
SVC | -0.903 |
HAPP | -0.893 |
PETV | -0.891 |
BLBD | -0.889 |
MLTX | -0.889 |
STRL | -0.886 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Jazz Pharmaceuticals PLC Koreliacija - Valiuta/Žaliavos
Jazz Pharmaceuticals PLC Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $3.83B |
Bruto pelnas: | $2.79B (72.78 %) |
EPS: | $6.55 |
FY | 2023 |
Pajamos: | $3.83B |
Bruto pelnas: | $2.79B (72.78 %) |
EPS: | $6.55 |
FY | 2022 |
Pajamos: | $3.66B |
Bruto pelnas: | $3.12B (85.23 %) |
EPS: | $-3.42 |
FY | 2021 |
Pajamos: | $3.09B |
Bruto pelnas: | $2.65B (85.76 %) |
EPS: | $-5.52 |
Financial Reports:
No articles found.
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.